Press Release
With reference to above subject, please find enclosed Press Release of our company titled 'Suven Life Sciences secures a Product Patent in New Zealand'28-03-2017
28-03-2017
Updates
Suven Life Sciences Ltd has informed BSE that Suven Life Sciences team is participating in "15th Annual Investors Conference India Unlimited with global money managers and analysts meet organized by ICICI Securities on February 06 07 , 2017 in Singapore & on February 08, 2017 in Hong Kong.03-02-2017
Suven LifeSciences - R&D investments paying off
Suven LifeSciences has seen a strong Q3 - albeit tempered from the Q2 this year - that will help the company end FY17 on a high note. The company declared a Q3 jump in net profit jump of 34.3% compared to the same quarter last year, with operating margins year on year helped by lower expenses and finance costs. QoQ performance for the company saw net profits fall 8.6%, although for the overall nine month period Suven's incomes are up 9.98% and profits up 32.77% compared to the previous year. The company has secured 5 product patents in neurodegenerative treatments over the financial year, including Alzheimer's treatments.01-02-2017
Board declares Interim Dividend
Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company, at its meeting held on February 01, 2017, has approved the following matters:1. The Board declared an interim dividend of Rs. 1/- per equity share of face value Rs 1/- each for the year 2016-2017.2. The above said dividend will be paid on and from February 16, 2017....01-02-2017
Communication to Investors December 2016
Suven Life Sciences Ltd has informed BSE regarding "Communication to Investors December 2016".01-02-2017
Standalone Financial Results, Limited Review Report, Results Press Release for December 31, 2016
Suven Life Sciences Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 20163. Result Press Release for the period ended December 31, 201601-02-2017
Company news
Suven Life Sciences has got a product patent in the US for a new chemical entity used in the treatment of disorders associated with neurodegenerative diseases. The patent is for mechanism of action...30-01-2017
Schedule of Conference Call for Investors
Suven Life Sciences Ltd has informed BSE regarding "Schedule of Conference Call for Investors".30-01-2017
Suven Life Sciences secures a Product Patent in USA
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated January 30, 2017 titled "Suven Life Sciences secures a Product Patent in USA".30-01-2017
Fixes Record Date for Interim Dividend
Suven Life Sciences Ltd has informed BSE that the Company has fixed February 09, 2017 as the Record Date for the purpose of payment of interim dividend to eligible shareholders, if considered and approved by the Board in its meeting to be held on February 01, 2017.23-01-2017